Social networks
4,166Activities
Entity types
Location
Emperor House, Pierhead St, Cardiff CF10 4PH, UK
Cardiff
United Kingdom
Employees
Scale: 11-50
Estimated: 24
Engaged corporates
0Added in Motherbase
1 year, 6 months agoAdvancing Medicines for a Brighter Future
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma.
MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.
Biodexa Pharmaceuticals is a biopharmaceutical company developing a pipeline of products aimed at cancers of the brain.